Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 132M | 136M | 82M | 79M | 6M |
| Gross Profit | 73M | 73M | 42M | 44M | 6M |
| Operating Income | 58M | 48M | 25M | 28M | 6M |
| EBITDA | 58M | 48M | 25M | 28M | 6M |
| Net Income | 56M | 46M | 22M | 20M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Industrials
Live Price
Offline$0.068
-38.18% today
1Y Change
-94.03%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Protect Pharmaceutical Corporation (PRTT) is a Industrials stock with listed on OTC. The stock last traded around $0.07 and down 94.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -2.9%, EPS growth of +22.5%, a dividend yield of 0.0%. What stands out right now is revenue -2.9%, EPS +22.5%, free cash flow 0.0% with operating margin 34.1% and ROIC 6.6%. Valuation is more restrained than many high-expectation growth names at P/E 0.1 and price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRTT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRTT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRTT Max Drawdown
-98.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRTT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.9M
-92.5% YoY
FY Net Income
$5.8M
-71.2% YoY
Free Cash Flow
-$13.0M
+79.9% YoY
Revenue Growth
-2.9%
EPS Growth
+22.5%
Gross Margin
55.2%
Net Margin
28.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 132M | 136M | 82M | 79M | 6M |
| Gross Profit | 73M | 73M | 42M | 44M | 6M |
| Operating Income | 58M | 48M | 25M | 28M | 6M |
| EBITDA | 58M | 48M | 25M | 28M | 6M |
| Net Income | 56M | 46M | 22M | 20M | 6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 18M | 1M | 40M | 74K |
| Total Assets | 418M | 366M | 344M | 366M | 20M |
| Total Liabilities | 85M | 90M | 114M | 161M | 14M |
| Shareholder Equity | 333M | 276M | 230M | 206M | 6M |
| Total Debt | 4M | 4M | 3M | 12M | 14M |
| Net Debt | -14M | -14M | 1M | -28M | 14M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-35.5% YoY
Capital Expenditures
20M
+73.7% YoY
Free Cash Flow
13M
+79.9% YoY
Key ratios
Gross Margin
55.2%
Operating Margin
34.1%
Net Margin
28.4%
ROE
6.9%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.